TY - JOUR
T1 - 3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood
AU - Ziegler, Anette G.
AU - Haupt, Florian
AU - Scholz, Marlon
AU - Weininger, Katharina
AU - Wittich, Susanne
AU - Löbner, Stephanie
AU - Matzke, Claudia
AU - Gezginci, Cigdem
AU - Riethausen, Stephanie
AU - Beyerlein, Andreas
AU - Zillmer, Stephanie
AU - Amoroso, Marie
AU - Coles, Rebecca
AU - Powell, Michael
AU - Furmaniak, Jadwiga
AU - Smith, Bernard Rees
AU - Winkler, Christiane
AU - Bonifacio, Ezio
AU - Achenbach, Peter
N1 - Publisher Copyright:
© Copyright 2016, Mary Ann Liebert, Inc. 2016.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background: Testing for beta cell autoantibodies is used for wide-scale identification of early stages of type 1 diabetes. This requires suitable screening assays. We aimed to establish screening that utilized a first step assay (3 Screen) able to detect autoantibodies to the target antigens glutamic acid decarboxylase-65 (GAD), insulinoma-associated antigen 2 (IA-2), and zinc transporter 8 (ZnT8) to identify children positive for multiple beta cell autoantibodies. Methods: An ELISA format was used where plates were coated with a mixture of recombinant GAD, IA-2, and ZnT8325W/R-dimer molecules. The performance was determined in venous blood from 686 first-degree relatives of patients with type 1 diabetes, and 200 patients at onset of type 1 diabetes, and applied as a screening assay in capillary blood from 33,639 general population children. Results: The 3 Screen assay sensitivity for detecting autoantibody-positive patients at onset of type 1 diabetes was similar to that achieved by separate radiobinding assays (RBAs) for antibodies to GAD, IA-2, and ZnT8. Results in venous and capillary serum were correlated (R = 0.987). At a threshold corresponding to the 98th centile (29.1 U/mL) of all 33,639 capillary samples, the 3 Screen was positive in 123 samples with two or more RBA-positive antibodies to insulin, GAD, IA-2, or ZnT8, 146 with one antibody, and 479 that were RBA negative for beta cell autoantibodies. Conclusion: A 3 Screen ELISA was developed that was suitable for first step screening of multiple beta cell autoantibodies in capillary blood.
AB - Background: Testing for beta cell autoantibodies is used for wide-scale identification of early stages of type 1 diabetes. This requires suitable screening assays. We aimed to establish screening that utilized a first step assay (3 Screen) able to detect autoantibodies to the target antigens glutamic acid decarboxylase-65 (GAD), insulinoma-associated antigen 2 (IA-2), and zinc transporter 8 (ZnT8) to identify children positive for multiple beta cell autoantibodies. Methods: An ELISA format was used where plates were coated with a mixture of recombinant GAD, IA-2, and ZnT8325W/R-dimer molecules. The performance was determined in venous blood from 686 first-degree relatives of patients with type 1 diabetes, and 200 patients at onset of type 1 diabetes, and applied as a screening assay in capillary blood from 33,639 general population children. Results: The 3 Screen assay sensitivity for detecting autoantibody-positive patients at onset of type 1 diabetes was similar to that achieved by separate radiobinding assays (RBAs) for antibodies to GAD, IA-2, and ZnT8. Results in venous and capillary serum were correlated (R = 0.987). At a threshold corresponding to the 98th centile (29.1 U/mL) of all 33,639 capillary samples, the 3 Screen was positive in 123 samples with two or more RBA-positive antibodies to insulin, GAD, IA-2, or ZnT8, 146 with one antibody, and 479 that were RBA negative for beta cell autoantibodies. Conclusion: A 3 Screen ELISA was developed that was suitable for first step screening of multiple beta cell autoantibodies in capillary blood.
UR - http://www.scopus.com/inward/record.url?scp=84997236730&partnerID=8YFLogxK
U2 - 10.1089/dia.2016.0199
DO - 10.1089/dia.2016.0199
M3 - Article
C2 - 27552135
AN - SCOPUS:84997236730
SN - 1520-9156
VL - 18
SP - 687
EP - 693
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 11
ER -